Literature DB >> 10867724

Nutrition and lung function in cystic fibrosis patients: review.

M H Schöni1, C Casaulta-Aebischer.   

Abstract

Complex interactions between nutrition, skeletal and respiratory muscle function and energy expenditure in cystic fibrosis patients exist. Malnutrition significantly contributes to muscle weakness in patients with chronic obstructive pulmonary disease of the adult or in cystic fibrosis in childhood. Together with a measurable increase in resting energy expenditure the malnutrition, as a consequence of pancreatic insufficiency, leads to pulmonary deterioration. Whether pulmonary disease, pancreatic insufficiency, increased energy expenditure or insufficient intake of nutrition are the starters for the destructive circle or whether the basic defect is responsible for some of the components interacting with each other remains to be determined. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10867724     DOI: 10.1054/clnu.1999.0080

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  8 in total

1.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

2.  Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.

Authors:  G Steinkamp; B Wiedemann
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

3.  Nutrient status of adults with cystic fibrosis.

Authors:  Catherine M Gordon; Ellen J Anderson; Karen Herlyn; Jane L Hubbard; Angela Pizzo; Rondi Gelbard; Allen Lapey; Peter A Merkel
Journal:  J Am Diet Assoc       Date:  2007-12

4.  Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.

Authors:  J Riethmueller; M Ballmann; T W Schroeter; P Franke; R von Butler; A Claass; S Junge; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553

5.  Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.

Authors:  J Riethmueller; S Junge; T W Schroeter; K Kuemmerer; P Franke; M Ballmann; A Claass; S Broemme; R Jeschke; A Hebestreit; D Staab; K Koetz; G Doering; M Stern
Journal:  Infection       Date:  2009-09-05       Impact factor: 3.553

Review 6.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

7.  Factors associated with severe lung disease in an adult population with cystic fibrosis: a single-center experience

Authors:  Berrin Er; Ebru Çelebioğlu; Ebru Yalçin; Deniz Doğru; Özlem Erden Aki; Ömrüm Uzun; Murat Akova; Uğur Özçelik; Nural Kiper; Salih Emri
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

Review 8.  Exercise Physiology Across the Lifespan in Cystic Fibrosis.

Authors:  Ren-Jay Shei; Kelly A Mackintosh; Jacelyn E Peabody Lever; Melitta A McNarry; Stefanie Krick
Journal:  Front Physiol       Date:  2019-11-05       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.